Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies

Monoclonal antibody based immune checkpoint blockade therapies have achieved clinical successes in management of malignant tumors. As the first monoclonal antibody targeting immune checkpoint molecules entered into clinics, the molecular basis of ipilimumab-based anti-CTLA-4 blockade has not yet bee...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: He, Mengnan, Chai, Yan, Qi, Jianxun, Zhang, Catherine W.H., Tong, Zhou, Shi, Yi, Yan, Jinghua, Tan, Shuguang, Gao, George F.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5620161/
https://ncbi.nlm.nih.gov/pubmed/28978021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18004
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires